MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 09 2025
0mins
Source: Globenewswire
RMAT Designation Granted: The FDA has awarded Regenerative Medicine Advanced Therapy (RMAT) designation to MeiraGTx's AAV-GAD for treating Parkinson’s disease, based on positive results from three clinical studies showing its potential as a one-time treatment.
Benefits of RMAT: This designation allows for increased regulatory interactions with the FDA and includes advantages like Fast Track and Breakthrough Therapy designations, potentially expediting the approval process for this innovative gene therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
